Drugs / HAVRIX 720
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01041573 Comparator | Mar 2010 → Feb 2011 | encephalitis | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00483470 Comparator | Jun 2007 → May 2008 | hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01307436 Comparator | Mar 2007 → Jul 2013 | hepatitis A virus infection | Crucell Holland BV | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Havrix720 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01041573 ↗ |
| Known as | Havrix | “Healthy anti-hepatitis A virus seronegative subjects aged 13 to 19 yr were randomized in three equal groups to receive two doses of Avaxim™, Epaxal®, or Havrix®, 6 to 12 months apart.” PMID 26770041 ↗ Dec 2015 |
| Modality | Vaccine | “Hepatitis A vaccine (HAVRIX 720)” NCT00483470 ↗ |
| Route | Intramuscular | “Havrix®720 0.5 ml im. at day 0 and month 7” NCT01041573 ↗ |